Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities

Marketable Securities

9 Months Ended

Sep. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Marketable securities consisted of the following as of:


September 30, 2024	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	2,328,472	$	1,754	$	—	$	2,330,226
Total	$	2,328,472	$	1,754	$	—	$	2,330,226


December 31, 2023	Amortized Cost		Unrealized Gain		Unrealized Loss		Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	4,085,996	$	877	$	—	$	4,086,873
Total	$	4,085,996	$	877	$	—	$	4,086,873

As of September 30, 2024, the Company held 11 U.S. Treasury debt securities that were in an unrealized gain position totaling $1,754. As of December 31, 2023, the Company held three U.S. Treasury debt securities that were in an unrealized gain position totaling $877. All U.S. Treasury obligations were due to mature in less than one year for the period and year ended September 30, 2024 and December 31, 2023, respectively.

The Company received proceeds of $12.1 million from maturities of marketable securities for the nine months ended September 30, 2024. The Company received proceeds of $41.1 million from maturities of marketable securities for the year ended December 31, 2023. The Company did not realize any gains or losses from maturities of marketable securities for the period ended September 30, 2024 or the year ended December 31, 2023.